Masafumi Ono
About
Masafumi Ono is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Masafumi Ono has authored 115 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Epidemiology, 44 papers in Hepatology and 30 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Masafumi Ono's work include Liver Disease Diagnosis and Treatment (70 papers), Diet, Metabolism, and Disease (25 papers) and Liver Disease and Transplantation (17 papers). Masafumi Ono is often cited by papers focused on Liver Disease Diagnosis and Treatment (70 papers), Diet, Metabolism, and Disease (25 papers) and Liver Disease and Transplantation (17 papers). Masafumi Ono collaborates with scholars based in Japan, United States and United Kingdom. Masafumi Ono's co-authors include Toshiji Saibara, Yuichiro Eguchi, Hideyuki Hyogo, Kazuaki Chayama, Yoshio Sumida, Saburo Onishi, Masato Yoneda, Atsushi Nakajima, Toshihiko Mizuta and Koji Fujita and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.
In The Last Decade
Masafumi Ono
107 papers receiving 4.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Masafumi Ono Japan | 34 | 3.8k | 1.9k | 1.7k | 766 | 723 | 115 | 4.9k | ||
| Toshiji Saibara Japan | 39 | 4.2k 1.1× | 2.2k 1.1× | 1.8k 1.0× | 868 1.1× | 1.3k 1.8× | 169 | 6.4k | ||
| Kento Imajo Japan | 40 | 4.2k 1.1× | 2.3k 1.2× | 1.5k 0.9× | 821 1.1× | 720 1.0× | 142 | 5.1k | ||
| Hideyuki Hyogo Japan | 42 | 4.4k 1.1× | 2.2k 1.1× | 1.9k 1.2× | 1.2k 1.6× | 930 1.3× | 127 | 6.2k | ||
| Alexander Wree Germany | 35 | 3.5k 0.9× | 1.5k 0.8× | 875 0.5× | 779 1.0× | 2.6k 3.6× | 90 | 6.0k | ||
| Hiroyuki Kirikoshi Japan | 36 | 2.1k 0.6× | 936 0.5× | 788 0.5× | 993 1.3× | 1.2k 1.6× | 138 | 4.0k | ||
| Toshihiko Mizuta Japan | 33 | 2.1k 0.5× | 1.4k 0.7× | 733 0.4× | 538 0.7× | 867 1.2× | 108 | 3.9k | ||
| Kazuhiro Kotoh Japan | 30 | 2.0k 0.5× | 1.3k 0.7× | 566 0.3× | 717 0.9× | 839 1.2× | 129 | 3.6k | ||
| Julie R. Jonsson Australia | 28 | 2.6k 0.7× | 2.1k 1.1× | 564 0.3× | 658 0.9× | 432 0.6× | 54 | 3.9k | ||
| Yuichi Nozaki Japan | 33 | 2.0k 0.5× | 759 0.4× | 902 0.5× | 624 0.8× | 743 1.0× | 78 | 3.2k | ||
| Karen Louise Thomsen Denmark | 27 | 2.1k 0.5× | 1.1k 0.6× | 583 0.3× | 625 0.8× | 574 0.8× | 104 | 3.0k |
Countries citing papers authored by Masafumi Ono
Since
Specialization
Citations
This map shows the geographic impact of Masafumi Ono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masafumi Ono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masafumi Ono more than expected).
Fields of papers citing papers by Masafumi Ono
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Masafumi Ono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masafumi Ono. The network helps show where Masafumi Ono may publish in the future.
Co-authorship network of co-authors of Masafumi Ono
This figure shows the co-authorship network connecting the top 25 collaborators of Masafumi Ono. A scholar is included among the top collaborators of Masafumi Ono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masafumi Ono. Masafumi Ono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tadokoro, Tomoko, Joji Tani, Kei Takuma, et al.. (2025). Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism. Internal Medicine. 64(15). 2307–2311.
2.
Tadokoro, Tomoko, Miwa Kawanaka, Kazuhiro Takahashi, et al.. (2025). A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index. Diagnostics. 15(8). 1023–1023.
3.
Fujita, Koji, Asahiro Morishita, Masafumi Ono, et al.. (2024). Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression. Biochemical Pharmacology. 226. 116321–116321.
4.
Koseki, Masahiro, Ayami Saga, Takeshi Okada, et al.. (2024). Tofogliflozin attenuates renal lipid deposition and inflammation <i>via</i> PPARα upregulation mediated by miR-21a impairment in diet-induced steatohepatitic mice. Endocrine Journal. 71(11). 1055–1067.
5.
Matsumoto, Kenichi, et al.. (2024). Tenascin-X is increased with decreased expression of miR-378a-5p and miR-486-5p in mice fed a methionine-choline-deficient diet that induces hepatic fibrosis. Biomedical Research. 45(2). 67–76.
6.
Tadokoro, Tomoko, Joji Tani, Kei Takuma, et al.. (2024). Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis. Scientific Reports. 14(1). 10784–10784.
7.
Nomura, Takako, Masafumi Ono, Kiyoyuki Kobayashi, et al.. (2023). Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex. Hepatology Research. 53(10). 968–977.
8.
Morishita, Asahiro, Kyoko Oura, Tomoko Tadokoro, et al.. (2023). MicroRNAs and Nonalcoholic Steatohepatitis: A Review. International Journal of Molecular Sciences. 24(19). 14482–14482.
9.
Oura, Kyoko, Asahiro Morishita, Kei Takuma, et al.. (2023). Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival. Cancer Medicine. 12(24). 22023–22037.
10.
Ono, Masafumi, Koji Fujita, Kiyoyuki Kobayashi, & Tsutomu Masaki. (2023). Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma. Hepatology Research. 53(7). 579–594.
11.
Kamada, Yoshihiro, Kensuke Munekage, Takashi Nakahara, et al.. (2022). The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD. Nutrients. 15(1). 66–66.
12.
Kamada, Yoshihiro, Takashi Nakahara, Kensuke Munekage, et al.. (2022). Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD. Hepatology Communications. 6(7). 1527–1536.
13.
Sumida, Yoshio, Masashi Yoneda, Katsutoshi Tokushige, et al.. (2021). FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life. 11(2). 143–143.
14.
Nakahara, Takashi, Masafumi Ono, Takumi Kawaguchi, et al.. (2021). Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Journal of Gastroenterology and Hepatology. 37(3). 592–599.
15.
Sumida, Yoshio, Masashi Yoneda, Katsutoshi Tokushige, et al.. (2020). Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 21(6). 1907–1907.
16.
Aikata, Hiroshi, Kazuaki Chayama, Kento Imajo, et al.. (2014). Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients Takashi NakaharaHideyuki HyogoMasato YonedaYoshio SumidaYuichiro EguchiHideki Fujii • Masafumi OnoTakumi KawaguchiKento ImajoHiroshi AikataSaiyu TanakaKazuyuki Kanemasa • Kazuma FujimotoKeizo AnzaiToshiji SaibaraMichio SataAtushi NakajimaYoshito Itoh • Kazuaki ChayamaTakeshi OkanoueJapan Study Group of Nonalcoholic Fatty Liver ….
17.
Taketani, Hiroyoshi, Yoshio Sumida, Saiyu Tanaka, et al.. (2013). The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. Journal of Gastroenterology. 49(7). 1163–1174.
18.
Nakamura, Akinobu, Masato Yoneda, Yoshio Sumida, et al.. (2013). Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in J apanese patients with non‐alcoholic fatty liver disease. Journal of Diabetes Investigation. 4(6). 651–658.
19.
Okanoue, Takeshi, Toshiji Saibara, Masafumi Ono, et al.. (2009). JSH Consensus Kobe 2009; Diagnosis and Treatment of NASH. Kanzo. 50(12). 741–747.
20.
Hashimoto, Takashi, Y Shimizu, T Suzuki, et al.. (1996). Living related donor liver transplantation: the Nagoya experience.. PubMed. 28(4). 2380–1.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Toshiji Saibara Breakdown of academic impact, for papers by Kento Imajo Breakdown of academic impact, for papers by Hideyuki Hyogo Breakdown of academic impact, for papers by Alexander Wree Breakdown of academic impact, for papers by Hiroyuki Kirikoshi Breakdown of academic impact, for papers by Toshihiko Mizuta Breakdown of academic impact, for papers by Kazuhiro Kotoh Breakdown of academic impact, for papers by Julie R. Jonsson Breakdown of academic impact, for papers by Yuichi Nozaki Breakdown of academic impact, for papers by Karen Louise Thomsen